Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: A multicenter, open-label, non-inferiority, randomized controlled study

Neurogastroenterology and Motility

Volumn 24, Issue 9, 2012, Pages

  Sohn, W ^a   Lee, O Y ^a   Kwon, J G ^b   Park, K S ^c   Lim, Y J ^d   Kim, T H ^e   Jung, S W ^f   Kim, J I ^e  

^a Hanyang University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Keimyung University School of Medicine   (South Korea)

^d Dongguk University College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Korea University College of Medicine   (South Korea)

Author keywords

Amitriptyline; Antidepressant; Irritable bowel syndrome; Tianeptine

Indexed keywords

AMITRIPTYLINE; PROBIOTIC AGENT; TIANEPTINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACILLUS SUBTILIS; BEDTIME DOSAGE; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; IRRITABLE COLON; KOREA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT DURATION; XEROSTOMIA;

ADULT; AGED; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DIARRHEA; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS; THIAZEPINES; TREATMENT OUTCOME;

EID: 84865440164     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01945.x     Document Type: Article

References (45)

1. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008; 358: 1692-9.
2. Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am 2011; 40: 1-10.
3. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am 2011; 40: 11-9.
4. Karantanos T, Markoutsaki T, Gazouli M, Anagnou NP, Karamanolis DG. Current insights in to the pathophysiology of irritable bowel syndrome. Gut Pathog 2010; 2: 19-26.
5. Chang JY, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci 2010; 31: 326-34.
6. Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009; 41: 854-62.
7. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381-96.
8. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003; 65: 528-33.
9. Faresjo A, Grodzinsky E, Johansson S, Wallander MA, Faresjo T, Timpka T. Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. J Manag Care Pharm 2008; 14: 870-7.
10. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl 1): S1-35.
11. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
12. McEwen BS, Chattarji S, Diamond DM et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010; 15: 237-49.
13. Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: a review of its use in depressive disorders. CNS Drugs 2001; 15: 231-59.
14. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
15. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108.
16. Vahedi H, Merat S, Momtahen S et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharm Ther 2008; 27: 678-84.
17. Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
18. Mulak A, Bonaz B. Irritable bowel syndrome: a model of the brain-gut interactions. Med Sci Monit 2004; 10: RA55-62.
19. Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001; 62 (Suppl 8): 38-45; discussion 46-37.
20. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43: 256-61.
21. Grover M, Drossman DA. Centrally acting therapies for irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 183-206.
22. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-709.
23. Bertrand PP, Bertrand RL. Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci 2010; 153: 47-57.
24. Dunlop SP, Coleman NS, Blackshaw E et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57.
25. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-70.
26. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43.
27. Gorard DA, Libby GW, Farthing MJG. Influence of antidepressants on whole gut and orocecal transit times in health and irritable-bowel-syndrome. Aliment Pharm Ther 1994; 8: 159-66.
28. Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat CNS Drug Discov 2006; 1: 29-41.
29. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151: 737-48.
30. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-58.
31. Bolton VN, Bassil AK, Lee K, Sanger GJ. Inhibition by tianeptine of neuronally mediated contractions in the rat isolated gastrointestinal tract. Pharmacol Res 2008; 57: 339-43.
32. Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008; 22: 15-26.
33. Vouimba RM, Munoz C, Diamond DM. Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala. Stress 2006; 9: 29-40.
34. Myers B, Greenwood-Van Meerveld B. Role of anxiety in the pathophysiology of irritable bowel syndrome: importance of the amygdala. Front Neurosci 2009; 3: 1-10.
35. Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011; 140: 761-5.
36. Jones MP, Dilley JB, Drossman D, Crowell MD. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91-103.
37. Delbende C, Tranchand Bunel D, Tarozzo G et al. Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis. Eur J Pharmacol 1994; 251: 245-51.
38. Uzbay TI. Tianeptine: potential influences on neuroplasticity and novel pharmacological effects. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 915-24.
39. McEwen BS, Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. Eur Neuropsychopharmacol 2004; 14(Suppl 5): S497-502.
40. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 738-41.
41. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-7.
42. Ham BJ, Kim YH, Choi MJ, Cha JH, Choi YK, Lee MS. Serotonergic genes and personality traits in the Korean population. Neurosci Lett 2004; 354: 2-5.
43. Fukudo S, Kanazawa M, Mizuno T et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage 2009; 47: 946-51.
44. Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials 1988; 9: 312-26.
45. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet 2002; 359: 515-9.